Form 4: Director Christopher Patusky Executes UTHR Stock Options

United Therapeutics Director Christopher Patusky exercised 1,000 stock options and sold the resulting shares under a 10b5-1 plan.

Summary

• Director Christopher Patusky exercised 1,000 stock options at a strike price of $101.80.
• Following the exercise, the director sold 1,000 shares of common stock at an average price of $578.88.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan established on December 18, 2025.
• The director retains 1,490 shares directly and 1,100 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was conducted under a pre-arranged 10b5-1 plan and represents standard portfolio management by a director.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.

Negatives

• The director reduced their direct beneficial ownership of common stock by 1,000 shares.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under pre-established 10b5-1 plans is a standard corporate governance practice and typically does not signal a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while avoiding potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Director Transaction